Karyopharm Therapeutics Inc. (KPTI) CEO Sells $91,600.00 in Stock
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $9.16, for a total value of $91,600.00. Following the sale, the chief executive officer now owns 522,143 shares in the company, valued at $4,782,829.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Karyopharm Therapeutics Inc. (KPTI) remained flat at $$9.15 on Wednesday. 173,400 shares of the company were exchanged, compared to its average volume of 234,014. Karyopharm Therapeutics Inc. has a 1-year low of $7.48 and a 1-year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. research analysts forecast that Karyopharm Therapeutics Inc. will post -2.58 EPS for the current year.
A number of brokerages have recently weighed in on KPTI. Royal Bank of Canada reiterated a “buy” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, October 18th. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 12th. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Finally, Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $17.33.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.